Bone marrow transplant and gene therapy in cerebral ALD
|
|
- Roy Dawson
- 5 years ago
- Views:
Transcription
1 Bone marrow transplant and gene therapy in cerebral ALD Dr Robert Chiesa Consultant in Bone Marrow Transplantation Great Ormond Street Hospital London 10:15 Dr Robert Chiesa- BMT/ Gene Therapy 1
2 Bone marrow transplant why the bone marrow (BM)? BM contains different cells including STEM CELLS and immune cells (T-cells); Stem cells have the ability to transform into different blood cells / cells forming the immune system / enzyme replacement; STEM CELL Stem cells from healthy donors can be collected (harvested) and transplanted (BMT) in patients with defective haematology/immunology/metabolics Immune cells prevent rejection & infections (viral) Stem cells can transform into different blood cells, and can be taken from bone marrow, peripheral blood or umbilical cord blood. Bone marrow transplants are used to treat blood conditions such as leukaemia. Over 2000 bone marrow transplants took place between
3 BMT sources of stem cells BONE MARROW: requires harvest in theatre/general anaesthesia for donor PERIPHERAL BLOOD: stimulation with G-CSF, collection of stem cells UMBILICAL CORD BLOOD: used since stored worldwide. 3
4 Indications to BMT in children Leukaemia Immunodeficiency Metabolic Bone marrow failure Inflammatory Bowel Diseases Rheumatoid Dermatology (EB) Thalassaemia Sickle cell disease 4
5 BMT in metabolic disorders ( ) Worldwide >2000 BMTs have been performed in IEM; 4 main diseases: MPS type I X-ALD MLD GLD MLD 5% 9% X-ALD 17% Other 13% MPS I Hurler syndrome 28% Osteopetrosis 18% Other MPS 10% Osteopetrosis CIBMTR database
6 BMT in lysosomal storage diseases (LSD) Lack of lysosomal enzymes; Enzyme is secreted by donor-derived (normal) cells and taken up by deficient cells; Cross correction of host cells. 6
7 How does BMT correct some LSD? 1 Chemo to eliminate patient s own stem cells 4 CNS Penetration donor cells 2 BMT Stem cell infusion 3 ENGRAFTMENT Migration and distribution donor derived-cells into host tissues The process is a combination of chemotherapy (eliminating the patient s own stem cells), infusing donor stem cells and grafting these on to the patient. A soluble enzyme secreted by the donor cells corrects cells in the patient. 7
8 Rationale for BMT in ALD Mechanism of action in ALD not entirely clear; ALDP is not a soluble enzyme (membrane-bound protein); Accumulation VLCFA may destabilize/damage myelin structure trigger inflammation; Donor-derived cells migration in the brain (microglia); Decrease oxidative stress/damage in tissues reduce inflammation; Immuno-modulatory properties of BMT The mechanism of how bone marrow transplants work for ALD is not clear, as ALD is not related to a soluble enzyme. A bone marrow transplant reduces inflammation, stress and damage, but it is not clear how this works. 8
9 Bone marrow transplantation steps DONOR SELECTION CONDITIONING REGIMEN STEM CELL INFUSION MANAGEMENT POST-BMT COMPLICATION & FOLLOW-UP Steps of a bone marrow transplant: Donor selection: tissue match needed between patient and donor. Preparation/Conditioning Regimen: Chemotherapy drugs are given to children to prepare them for transplant over the course of the 7-9 days before infusion of stem cells. Stem cell infusion Long follow up to monitor and tackle the consequences of conditioning 9
10 DONOR SEARCH tissue typing Blood tests to verify the presence of a tissue-matched donor (in the family or unrelated); PATIENT DONOR 1 A fully matched family donor is found in 25-30% patients; The chance of finding a fully matched unrelated donor depends upon the recipient s ethnic background (70% Caucasians vs 10% non-caucasians); = 10/10 25% find a match within their family. The chances of finding a fully matched unknown donor depend on race: Caucasians have a 70% chance of finding a match, while other races and those of mixed race will have much lower chances. 10
11 DONOR SEARCH tissue typing Blood tests to verify the presence of a tissue-matched donor (in the family or unrelated); PATIENT DONOR 2 A fully matched family donor is found in 25-30% patients; The chance of finding a fully matched unrelated donor depends upon the recipient s ethnic background (70% Caucasians vs 10% non-caucasians); The use of mismatched donors increases transplant-related toxicity; = 09/10 The use of mismatched donors increases the risk of transplant related toxicity. 11
12 DONOR SEARCH tissue typing Blood tests to verify the presence of a tissue-matched donor (in the family or unrelated); PATIENT DONOR 3 A fully matched family donor is found in 25-30% patients; The chance of finding a fully matched unrelated donor depends upon the recipient s ethnic background (70% Caucasians vs 10% non-caucasians); The use of mismatched donors increases transplant-related toxicity; = 05/10 Parents can be donors, but they will only have a 50% match 12
13 PREPARATIVE REGIMEN Chemotherapy (rarely radiotherapy) to prepare the patient to receive the transplant; Given over 7-9 days prior to the transplant; Two main components of the preparative regimen: - myeloablation (create space in the bone marrow) - immunosuppression (prevent graft rejection) Preparation/Conditioning Regimen: Chemotherapy drugs are given to children to prepare them for transplant over the course of the 7-9 days before infusion of stem cells. Myeloablation is used to create space in the bone marrow for new cells Immunosuppressants prevent graft rejection 13
14 PREPARATIVE REGIMEN intensity hierarchy Drugs are used in different combinations to produce a range of conditioning from mild to strong Minimal Intensity Conditioning ( MIC ) Reduced Intensity Conditioning ( RIC ) Myeloablative Intensity Conditioning ( MAC ) Different combinations of drugs are needed for different conditions- bone marrow transplants for ALD require the strongest combination- MAC. 14
15 PREPARATIVE REGIMEN toxicity Depends on the intensity of conditioning (RIC vs MAC) Acute (I): nausea, vomit, lethargy Acute (II): inflammation/pain mouth & gut, transient hair loss, organ toxcity (liver, kidneys, lungs), low immunity and infections Effective supportive treatment provided Late : possible effects on fertility / other.. The toxicity of drugs can cause nausea, vomiting and lethargy, with longer term possible side effects including inflammation, pain in the mouth, hair loss, low immunity causing infections, organ toxicity and potential infertility. 15
16 GRAFT REJECTION When the patient s residual immune system does not recognize the graft and fights it / rejects it; The preparative regimen weakens the patients immune system, so that the patient is more tolerant ; The immunosuppressants (like cyclosporine) have to continue for a few months after BMT In a fully matched graft, there is a 5% chance that the immune system will fight and reject the graft. This chance is higher in a mismatched graft. Preparation and immunosuppressants are used to prevent graft rejection 16
17 GRAFT VERSUS HOST DISEASE (GvHD) When the immune cells (lymphocytes) infused with the bone marrow do not recognize the patient and fight; Acute GvHD: commonly skin rash. Less commonly diarrhea or liver/lung disease; Treatment: more immunosuppression (drugs): resolution in 80% cases. There is also a risk of Graft Vs Host Disease (GVHD), which is the opposite of graft rejection. In GVHD, the graft does not recognise the patient and fights back against host cells. Immunosuppressants resolve this in 80% of cases. 17
18 Bone marrow transplantation Preparative regimen 7-9 days 18
19 Bone marrow transplantation BMT Preparative regimen 7-9 days 19
20 Bone marrow transplantation Preparative regimen BMT Acute toxicity Bacterial/ fungal infections Low counts 7-9 days days 2-3 weeks after transplant, children experience acute toxicity of the chemotherapy, including immunodeficiencies leaving them vulnerable to bacterial, fungal and viral infections 20
21 FIRST RESULT AFTER BMT ENGRAFTMENT / CHIMERISM SCENARIO N.1 SCENARIO N.2 SCENARIO N.3 100% donor engraftment mixed chimerism rejection PATIENT CELLS FULL ENGRAFTMENT DONOR CELLS After 2-3 weeks, white blood cells will have been produced by the new cells. Blood samples are sent to a laboratory to give the first indications as to the success of the procedure. Results will be one of 3 options: All white blood cells are from the donor, showing a full and successful engraftment Mixed chimerism: some white blood cells from the host have survived, alongside donor cells. Many diseases can still be cured even when some patient white blood cells have survived Rejection: no white blood cells are from the donor. There is a 5% chance of this happening. 21
22 Bone marrow transplantation Acute GvHD chronic GvHD Preparative regimen BMT Acute toxicity Bacterial/ fungal infections Low counts Viral reactivations Immuno suppression Count recovery Gradual weaning immunosuppressants Gradual immune reconstitution 7-9 days days days 3-12 months 11 months after the transplant, children can still have weak immune systems and be at risk of viral infection. The immune system should begin to strengthen after around 5 months. After 12 months, the child s care is handed over to the metabolic team. 22
23 BMT in X-ALD History 1990: first successful BMT in 8y old boy with cald: normal VLCFA levels and stabilization disease; 1997: 3 Swedish boys after BMT poor outcome for 2 symptomatic patients, suggesting early intervention; 1998: first successful use of cord blood transplant advantage as rapid stem cell source; 2004: Report on 126 boys with cald post-bmt(peters et al) main cause of death was progression of ALD. Higher risk if symptomatic pre-bmt. The first successful bone marrow transplant for ALD took place on an 8 year old in Bone marrow transplants on 3 Swedish boys in 1997 were successful in just 1/3 cases, as the condition of the boys was too advanced. This highlighted the need for early intervention for bone marrow transplants for ALD. From 1998, stem cells from umbilical cord blood have been used for bone marrow transplants, as these are a rapid stem cell source In 2004, an international study was conducted on 126 boys with ALD diagnoses. This again showed a higher risk in transplants occurring after symptoms arose. Progression of ALD was the main cause of death for those for whom the transplant was not successful 23
24 Measuring Neurologic and Radiographic Progression in CALD Neurologic Function Score (NFS) 1 Component Hearing/auditory processing problems Score Aphasia/apraxia 1 Loss of communication 3 Vision impairment 1 Cortical blindness 2 Swallowing dysfunctions 2 Tube feeding 2 Running difficulties 1 Walking difficulties/ spasticity 1 Spastic gait (need assistance) 2 Wheelchair dependence 2 No voluntary movement 3 Episodes of incontinence 1 Total incontinence 2 Non-febrile seizures 1 Possible Total Moser et al. Neuropediatrics 2000;31: Loes et al. AJNR Am J Neuroradiol 1994;15: Loes MRI severity score 2 : Measurement of white matter changes by degree and extent of pathological hyperintense regions (0-34) Loes score = 1 Loes score = 15 Gadolinium enhancement: Indicator of active inflammation A scoring system called NFS was set up to establish children s neurological conditions for prognostics prior to BMT. This is combined with a clinical Loes score, established from MRI scans, to determine probability of success of bone marrow transplant. Timing of the bone marrow transplant is therefore critical. GdE + 24
25 BMT in X-ALD Results 60 consecutive boys with X-ALD in single Institution; Analysis risk factors; 70% MAC, 30% RIC protocol; 50% UCBT, 50% BM; 70% early stage, 30% advanced disease. 25
26 BMT in X-ALD Results Survival depends on MRI changes and neurology at BMT; Timing BMT crucial; No difference EFS according to stem cell source. 26
27 BMT in X-ALD Conclusions Comparison of transplanted patients with historical untreated patients show striking survival advantage for BMT patients (Mahmood et al) ; Best neurological outcome in patients with NFS=0 and Loes <10 at time of BMT; Limited role of BMT in advanced disease;? Role BMT in prevention of AMN (3/5 adults with AMN post BMT, Geel et al); The role of transplants in the prevention of AMN is not well studied; transplants may not prevent AMN. 27
28 Who, when & how to transplant Early diagnosis ALD (newborn screening); MRI monitoring for detection cald; Urgent BMT if gad +ve changes or expanding white matter changes on sequential scans, before neurological changes; Choice of best available donor (HLA matched); Busulfan-based conditioning regimen Early diagnosis is needed, through New Born Screening and monitoring of MRI scans. Transplants become urgent when changes start to appear on scans, before neurological changes take place. These should use the best available donor, fully matched if possible. 28
29 Limitations of BMT Risk Treatment-related mortality % of patients 10% 1-4 Graft failure ~5% 1,4 Acute grade II-IV GVHD 10-40% 1-4 Chronic GVHD 10-20% 3,4 Full HLA donor match is required for best outcomes 1 1. Miller et al, Blood 2011; 2. Peters et al, Blood 2004; 3, Beam et al, Biol Blood Marrow Transplant. 2007; 4. Mitchell et al, Pediatr Transplant. 2012; 5. Martin et al, Biol Blood Marrow Transplant Bone Marrow Transplants have limitations, as there are risks involved: Risk of death by infection ~10% Risk of graft failure ~5% Risk of Graft Vs Host Disease ~30% 29
30 Gene therapy DNA is introduced into a patient to treat a genetic disease; The new DNA usually contains a healthy gene to correct the effects of a disease-causing mutation; First clinical trials in 80 s; Extensive experience in primary immunodeficiencies; GT in other mono-genetic disorders (metabolic diseases) Gene therapy is an alternative approach, used to correct genetic diseases by treating the patient s own DNA. It can be used instead of a bone marrow transplant if there is no donor match available. The first trials of gene therapy took place in the 1980s, and this is now expanding to treat many metabolic diseases. 30
31 Starbeam Study: Open-label, Single-arm Phase 2/3 Study of Lenti-D in cald Key enrollment criteria: Age 17 years, evidence of active CALD (GdE+) with early disease (Loes score , NFS 1), no matched sibling donor for allo-hsct Primary efficacy outcome: Proportion of patients who are alive and MFD-free at 24 months Primary safety outcome: Proportion of patients who experience Grade 2+ acute GVHD or chronic GVHD at 24 months post-treatment Secondary and exploratory efficacy outcomes: Changes in NFS, GdE+ resolution, overall survival, and change in Loes score Additional key safety parameters: Engraftment failure, adverse events, detection of replication-competent lentivirus, insertional oncogenesis Eichler et al. NEJM 2017;377: The STARBEAM Study is a gene therapy trial, monitoring patients for 2 years after therapy to see changes in MRI, toxicity and so on. The study used a carefully selected group who showed limited signs of the disease when the process began. 31
32 Starbeam Study: Treatment Protocol Lenti-D Drug Product consists of an autologous CD34+ cell-enriched population that contains cells transduced with lentiviral vector that encodes an ABCD1 cdna for human 32 ALDP 32
33 Patient Enrollment and Baseline Characteristics Baseline Characteristics (N=21) Parameter Median (range) 21 subjects treated as of August 25, 2017 Median follow-up 30.2 months (1-46 months) 4 patients with 4 months of follow-up Age at consent (years) 6.0 (4-13) Time from CALD diagnosis to treatment (months) Time from consent to treatment (days) 4.7 ( ) 66 ( ) Baseline Loes score 2.0 ( ) Baseline NFS score 0 (0-0) MFDs present at baseline None 33 33
34 Primary Endpoint Assessments Primary Endpoints Patient 2018 Patient 2016 Remaining Cohort Proportion of patients who are alive and MFD-free at 24 months Experienced rapid disease progression early on-study eventually resulting in MFDs and death Withdrew from study due to radiologic progression as evidenced by MRI Went on to receive an allo- HSCT and died due to transplant complications 15/17 (88%) remain MFD-free at 24 months 1 Historical data suggest ~75% of comparable patients receiving allo-hsct remain MFD-free at 2 years 2-5 % of patients who experience Grade 2+ agvhd or cgvhd at 24 months posttreatment All patients were free of GVHD 1. Eichler et al. NEJM 2017;377: Raymond et al. ALD-101 (in preparation); 3. Peters et al. Blood 2004;104: Miller et al. Blood 2011;118: Beam et 34 al. Biol Blood Marrow Transplant. 2007;13: Baumann et al. Eur J Pediatr 2003;162:6-14. Of 17 patients involved, 15 had survived 2 years after the beginning of the process, with 1 of the 2 deaths occurring in surgery complications. The remaining 15 show no signs of major disability. Longer follow up is needed on this. 34
35 Secondary Efficacy Endpoint: NFS NFS was stable in 18 patients with evaluable data 1 Stable NFS: score of 4 without an increase in >3 points since baseline NFS consistent with those seen after allo-hsct in patients with similar baseline disease characteristics 2 1. Eichler F. Child Neurology Society, Raymond et al. ALD-101 manuscript (in preparation) 35 35
36 Exploratory Efficacy Endpoint: Loes Scores Loes scores have stabilised in 15/20 patients at last visit 1* Stable Loes score: change of 5 points or an absolute Loes score 9 Loes scores consistent with those seen after allo-hsct in patients with similar baseline disease characteristics 2 1. Eichler F. Child Neurology Society, Raymond et al. ALD-101 manuscript (in preparation). *Excludes patient 2016 who had a stable Loes score at last visit 36 36
37 Subject ID Secondary Endpoint: gadolinium Enhancement GdE- GdE+ By Month 24, 11 of 15 patients were negative for gadolinium enhancement 1 Early results suggest no correlation between post-treatment gadolinium enhancement status and clinical outcomes 2 In all patients who had reemergence of gadolinium enhancement, the enhancement was less extensive than that seen at baseline 1. Eichler F. Child Neurology Society, Eichler et al. N Engl J Med 2017;377:
38 Safety Data Profile consistent with myeloablative conditioning Parameter Drug Product Cell Dose (x10 6 /kg) Neutrophil engraftment 1 (n=21; with and without GCSF) Median (min, max) 10.5 (6.0, 19.4) Day +13 (11, 39) Platelet engraftment 2 (n=18) Day (16, 55) 1. 3 consecutive absolute neutrophil count values of 0.5 x 10 9 /L obtained on different days consecutive platelet values 20 x 10 9 /L obtained on different days (unsupported) No graft failure or GVHD No insertional oncogenesis No replication competent lentivirus detected to date AEs consistent with myeloablative conditioning Grade 3 non-lab AEs in >1 subject C < NE (N=21) NE to M24 (N=21) Febrile neutropenia 17 (81%) 0 Stomatitis 6 (29%) 0 Nausea 4 (19%) 0 Vomiting 2 (10%) 0 Decreased appetite 9 (43%) 0 Hypokalaemia 4 (19%) 0 Epistaxis 2 (10%) 0 C = date of the start of conditioning; < NE = the day before neutrophil engraftment; NE = neutrophil engraftment Three AEs considered related or possibly related to drug product: BKmediated viral cystitis (SAE, grade 3), tachycardia (grade 1), vomiting (grade 1) These AEs and SAEs resolved with standard measures Data as of August 25,
39 Gene therapy in cald summary Of the 17 patients who completed 24 months of follow-up, 15 (88%) remain alive and free of major functional disabilities; No graft failure or GvHD reported to date Adverse events profile consistent with myeloablative conditioning with busulfan and cyclophosphamide Additional follow-up is ongoing to assess durability of effect and long-term safety 39 39
40 ?THERAPEUTIC OPTIONS Sir Luke Fildes The doctor 40
41 THERAPEUTIC OPTIONS CONVENTIONAL BMT GENE THERAPY Established treatment Long term follow-up Excellent results with fully matched donor Reduced TRM No GVHD Good preliminary neurological outcome Mortality 10% Risk of rejection/gvhd Use of mismatched donor Limited follow-up? Role gad +ve MRI post-gt 41
42 CONCLUSIONS BMT is the standard of care for c-ald, with good outcomes when performed early in pre-symptomatic patients; Importance NBS/early diagnosis; Role of BMT in more advanced disease is uncertain; Unclear if BMT can prevent AMN (possibly not); Risk of TRM and GVHD, especially when mismatched donors are used; Gene therapy is a promising alternative to BMT when matched donor is not found GT: good preliminary neurological & safety data. No risk of GVHD; GT: needs long term follow up; Importance of counselling families regarding available strategies. Summary: There are 2 options available for those with ALD, as long as early diagnosis has occurred: bone marrow transplant and gene therapy. Bone marrow therapy is a more established approach, with a longer follow-up history, but this requires a matched donor: mortality is ~10% higher for transplants with mismatched donors. Longer follow up is needed on the effects of gene therapy on ALD patients. Counselling for families is essential in both cases. It is possible that bone marrow therapy cannot stop AMN, as there is limited evidence of this 42
Hematopoietic Stem Cell Transplantation for Adrenoleukodystrophy
Hematopoietic Stem Cell Transplantation for Adrenoleukodystrophy 2011 NHLBI Pediatric Workshop Sept. 14, 2011 Paul Orchard, M.D. Division of Pediatric Blood and Marrow Transplant University of Minnesota
More informationLenti D for adrenoleukodystrophy in boys NIHRIO (HSRIC) ID: 7992 NICE ID: 8732
NIHR Innovation Observatory Evidence Briefing: May 2017 Lenti D for adrenoleukodystrophy in boys NIHRIO (HSRIC) ID: 7992 NICE ID: 8732 LAY SUMMARY Adrenoleukodystrophy (ALD), otherwise known as Lorenzo
More informationBlood and Marrow Transplant (BMT) for Sickle Cell Disease
Blood and Marrow Transplant (BMT) for Sickle Cell Disease Rhiannon is now cured of sickle cell disease after BMT. Blood and marrow transplant (BMT) is a proven cure for sickle cell disease. This handbook
More informationRob Wynn RMCH & University of Manchester, UK. HCT in Children
Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationUNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE
UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE Naynesh Kamani, M.D. Children s National Medical Center GW University School of Medicine Washington, DC SCD scope of problem in USA Commonest
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationSickle Cell Diseasechronic. curable disease? Objectives. Why would a family ask about cure for SCD?
Sickle Cell Diseasechronic illness or curable disease? Gregory M.T. Guilcher MD, FRCPC, FAAP Objectives To review the general principles of hematopoietic stem cell transplantation (HSCT), including risks
More informationNeutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt
Neutrophil Recovery: The First Step in Posttransplant Recovery No conflicts of interest to disclose Bus11_1.ppt Blood is Made in the Bone Marrow Blood Stem Cell Pre-B White cells B Lymphocyte T Lymphocyte
More informationAre We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell. Ann Haight, MD 9 Sept 2017
Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell Ann Haight, MD 9 Sept 2017 Spoiler alert Yes (we have a cure) And No Work to do! 2 Sickle Cell Treatment Options Supportive Care
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationThe National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient
1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationGene Therapy for ALD and AMN
Gene Therapy for ALD and AMN May 5 th, 2018 ALD Life Meeting Florian Eichler, MD Massachusetts General Hospital Department of Neurology 12:05 Dr Florian Eichler- Research on gene therapy for ALD and AMN
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation Current Results John E. Wagner, M.D. Blood and Marrow Transplant Program and Stem Cell Institute University of Minnesota Donor Choices Unrelated Marrow/PBSC Results
More informationHAEMATOPOIETIC STEM CELL TRANSPLANTATION
PRIMARY IMMUNODEFICIENCIES HAEMATOPOIETIC STEM CELL TRANSPLANTATION HAEMATOPOIETIC STEM CELL TRANSPLANTATION 1 PRIMARY IMMUNODEFICIENCIES KEY ABBREVIATIONS CID GvHD HSCT IPOPI PID SCID BMT HSC Combined
More informationPost Transplant Management for Sickle Cell. Title
Post Transplant Management for Sickle Cell Title Kimberly Kasow, DO October 14, 2016 Thank you for this opportunity to present this information I have no financial interests to disclose. Goal of Transplant
More informationCOHEM Barcellona 2012 Hemoglobinopathies debate
COHEM Barcellona 2012 Hemoglobinopathies debate September 8, 2012: h. 10:30-12:00 Hall: A Is it justified to perform BMT in hemoglobinopathies using unrelated and/or partially mismatched donors? HSCT indication
More informationStem cell transplantation. Dr Mohammed Karodia NHLS & UP
Stem cell transplantation Dr Mohammed Karodia NHLS & UP The use of haemopoeitic stem cells from a donor harvested from peripheral blood or bone marrow, to repopulate recipient bone marrow. Allogeneic From
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More informationNa#onal Neutropenia Network Family Conference July 12, 2014
Na#onal Neutropenia Network Family Conference July 12, 2014 Jim Connelly, MD Assistant Professor of Pediatrics and Communicable Diseases Blood and Marrow Transplant Program University of Michigan Transplant
More informationUKALL14. Non-Myeloablative Conditioning Regimen (1/1) Date started (dd/mm/yyyy) (Day 7) Weight (kg) BSA (m 2 )
Non-Myeloablative Conditioning Regimen (1/1) started (dd/mm/yyyy) (Day 7) BSA (m 2 ) Weight (kg) Please enter the daily dose given in the table below: Day Fludarabine (mg) Melphalan (mg) Alemtuzumab (mg)
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationBone Marrow (Stem Cell) Transplant for Sickle Cell Disease
Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease 1 Produced by St. Jude Children s Research Hospital Departments of Hematology, Patient
More information3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)
3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day
More informationMaking Hope A Reality December 10, Nasdaq : BLUE
Making Hope A Reality December 10, 2014 Nasdaq : BLUE Forward Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationHematopoietic Stem Cell Transplant in Sickle Cell Disease- An update
Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant
More informationSymptom management for adult males and update on adult BMT in UK
Symptom management for adult males and update on adult BMT in UK Robin Lachmann National Hospital for Neurology and Neurosurgery 12:05 Dr Robin Lachmann- Symptom management for adult males and update on
More informationHaploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia
Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal
More informationWhat s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016
What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationTransplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust
Transplantation - Challenges for the future Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Bone Marrow Transplantation Timeline, 1957-2006 Appelbaum F. N Engl J Med 2007;357:1472-1475
More informationGeneral Terms: Appendix B. National Marrow Donor Program and The Medical College of Wisconsin
Glossary of Terms This appendix is divided into two sections. The first section, General Terms, defines terms used throughout the CIBMTR data collection forms. The second section, FormsNet TM 2 Terms,
More informationCONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints
CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential
More informationOneMatch Stem Cell and Marrow Network. Training Guide
OneMatch Stem Cell and Marrow Network Training Guide What is OneMatch all about? OneMatch is a Canadian Program that matches and coordinates the collection of stem cells from potential donors to help save
More informationEBMT Complications and Quality of Life Working Party Educational Course
EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationNiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials
NiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials Mitchell E. Horwitz, MD Duke University Medical Center Duke Cancer Institute Adult Umbilical Cord Blood Transplantation
More informationDEPARTMENT OF CLINICAL HEMATOLOGY
DEPARTMENT OF CLINICAL HEMATOLOGY What is blood? Blood is the vital fluid of the body, which performs diverse functions from delivering oxygen to each and every cell of the body to fighting against infections
More informationLong Term Follow-Up Clinical Guidelines for X-linked Adrenoleukodystrophy
Long Term Follow-Up Clinical Guidelines for X-linked Adrenoleukodystrophy Gerald Raymond, M.D. Department of Pediatrics and Neurology Penn State Medical Center Hershey, PA June 20, 2018 Disclosure Information
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationFederica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1
Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,
More informationHaplo vs Cord vs URD Debate
3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor
More informationHematopoietic Stem Cell Transplantation for Fanconi Anemia
Hematopoietic Stem Cell Transplantation for Fanconi Anemia John E. Wagner, M.D. Blood and Marrow Transplant Program University of Minnesota Cell Therapy for Pediatric Diseases NHLBI PACT Workshop 14 15
More informationNEMO deficiency syndrome
NEMO NEMO deficiency syndrome hello@piduk.org 0800 987 8986 www.piduk.org About this leaflet This leaflet has been produced jointly between PID UK, Great Ormond Street Hospital (GOSH) and the Great North
More information1 Kattamis et al. Growth of Children with Thalassemia: Effect of Different Transfusion Regimens. Archives of
Objectives Sickle Cell Anemia and Thalassemia: Transplantation Provide overview of hemoglobinopathies: Sickle cell disease and Thalassemia Discuss approaches to therapy Review recent registry collaboration
More informationSwiss Summary of the Risk Management Plan (RMP) for BLINCYTO (Blinatumomab)
Swiss Summary of the Risk Management Plan (RMP) for BLINCYTO (Blinatumomab) RMP Summary: Version 1, April 2017 EU RMP: Version 3.2, November 2016 Page 1 of 13 The Risk Management Plan (RMP) is a comprehensive
More informationDisclosures. Neena Kapoor No disclosures. Daria Pagliara No disclosures. Mary Slatter No disclosures. Alice Bertaina No disclosures
Administration of BPX-501 Cells Following α/β T-cell and B-cell-Depleted HLA-Haploidentical HSCT (haplo-hsct) in Children with Primary Immunodeficiencies Daria Pagliara 1, Alice Bertaina 1,2, Mary Slatter
More informationThe role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.
The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness. Robert Liwski, MD, PhD, FRCPC Medical Director HLA Typing Laboratory Department of Pathology Dalhousie
More informationAcute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University
Acute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University Graft-versus-Host Disease (GVHD) Background GVHD is an immunologic reaction of the donor immune cells (Graft) against
More informationIntroduction to Hematopoietic Stem Cell Transplantation
Faculty Disclosures Introduction to Hematopoietic Stem Cell Transplantation Nothing to disclose Jeanne McCarthy-Kaiser, PharmD, BCOP Clinical Pharmacist, Autologous Stem Cell Transplant/Long- Term Follow-Up
More informationNothing to disclose. Title of the presentation - Author
Nothing to disclose Title of the presentation - Author 1 www.ebmt.org Complications after HSCT Alicia Rovó MD London 9/04/2013 Introduction Risk factors for transplant complication Type of complications
More informationSummary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016
Page 1 of 8 Date: July 22, 2016 Summary of Changes Page BMT CTN 1205 Protocol #4 Dated July 22, 2016 The following changes, and the rationale for the changes, were made to the attached protocol in this
More informationBack to the Future: The Resurgence of Bone Marrow??
Back to the Future: The Resurgence of Bone Marrow?? Thomas Spitzer, MD Director. Bone Marrow Transplant Program Massachusetts General Hospital Professor of Medicine, Harvard Medical School Bone Marrow
More informationDonatore HLA identico di anni o MUD giovane?
Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events
More informationUnderstanding the role of ex vivo T cell depletion
Prevention of graftversus-host disease (GVHD) Understanding the role of ex vivo T cell depletion Information for patients undergoing allogeneic stem cell transplantation in AML and their families 2 This
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001
More informationRelated haploidentical donors versus matched unrelated donors
Related haploidentical donors versus matched unrelated donors Bronwen Shaw, MD PhD Professor of Medicine, MCW Senior Scientific Director, CIBMTR Definition Matched Unrelated donor Refers to HLA matching
More informationMyeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris
Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,
More informationIntroduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018
Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell
More informationWISKOTT-ALDRICH SYNDROME. An X-linked Primary Immunodeficiency
WISKOTT-ALDRICH SYNDROME An X-linked Primary Immunodeficiency WHAT IS WISKOTT ALDRICH SYNDROME? Wiskott-Aldrich Syndrome (WAS) is a serious medical condition that causes problems both with the immune system
More informationHematopoietic stem cell mobilization and collection. Koen Theunissen Hematologie Jessa Ziekenhuis Hasselt Limburgs Oncologisch Centrum
Hematopoietic stem cell mobilization and collection Koen Theunissen Hematologie Jessa Ziekenhuis Hasselt Limburgs Oncologisch Centrum Transplants Transplant Activity in the U.S. 1980-2010 14,000 12,000
More informationBone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa
Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions
More informationUMBILICAL CORD BLOOD STEM CELLS EXPANDED IN THE PRESENCE OF NICOTINAMIDE (NICORD) PROVIDE LONG TERM MULITI-LINEAGE ENGRAFTMENT
UMBILICAL CORD BLOOD STEM CELLS EXPANDED IN THE PRESENCE OF NICOTINAMIDE (NICORD) PROVIDE LONG TERM MULITI-LINEAGE ENGRAFTMENT Mitchell E. Horwitz, MD Duke University Medical Center Duke Cancer Institute
More informationHaemophagocytic lymphohistiocytosis (HLH)
HLH Haemophagocytic lymphohistiocytosis (HLH) Information for families hello@piduk.org 0800 987 8986 www.piduk.org About this leaflet This booklet has been produced jointly between PID UK, Great Ormond
More information2016 BMT Tandem Meetings
ASBMT CIBMTR 2016 BMT Tandem Meetings for Prevention of Cytomegalovirus after Allogeneic Hematopoietic Cell Transplantation in CMV-Seropositive Patients A Randomized, Double-Blind, -Controlled, Parallel-Group
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationDr.PSRK.Sastry MD, ECMO
Peripheral blood stem cell transplantation (Haematopoietic stem cell transplantation) Dr.PSRK.Sastry MD, ECMO Consultant, Medical Oncology Kokilaben Dhirubhai Ambani Hospital Normal hematopoiesis Historical
More informationApproach to the Transplant Patient. Amy Musiek, MD AAD Annual Meeting 2018
Approach to the Transplant Patient Amy Musiek, MD AAD Annual Meeting 2018 Disclosures Actelion: speaker, advisory board, investigator Elorac: investigator Kyowa: investigator, advisory board Seattle genetics:
More informationHistocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director
Histocompatibility Evaluations for HSCT at JHMI M. Sue Leffell, PhD Professor of Medicine Laboratory Director JHMI Patient Population Adults Peds NMDP data >20,000 HSCT JHMI HSCT Protocols Bone marrow
More informationCHAPTER 2 PROTOCOL DESIGN
CHAPTER 2 PROTOCOL DESIGN CHAPTER 2 PROTOCOL DESIGN 2.1 ELIGIBILITY CRITERIA Participants fulfilling the following criteria will be eligible for enrollment in the protocol: 1. Participant is diagnosed
More informationDisclosures of: Emanuele Angelucci
Company name Novartis Disclosures of: Emanuele Angelucci Research support Employee Consultant Stockholder Speakers bureau Advisory board Chair of TELESTO pro Other EBMT 2012 Educational Session Haemoglobinopathy
More informationStem cell transplantation for haemoglobinopathies. Dr P J Darbyshire Birmingham Childrens Hospital
Stem cell transplantation for haemoglobinopathies Dr P J Darbyshire Birmingham Childrens Hospital Survival by Cohort of Birth (N=977) 1.00 85-97 80-84 75-79 70-74 0.75 Survival Probability 0.50 0.25 P
More informationCarol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT
Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT History Why is blood transfusion involved? What tests are performed in blood transfusion and why? What does a protocol look
More informationHaemopoietic Stem Cell Transplantation
Haemopoietic Stem Cell Transplantation Current Status in Paediatric Disorders HSCT! Replacement of recipient HSC and derived lineages, by donor HSC! Unique organ transplant! Regenerative tissue! both recipient
More informationDisclosure. Objectives 1/22/2015
Evaluation of the Impact of Anti Thymocyte Globulin (ATG) on Post Hematopoietic Stem Cell Transplant (HCT) Outcomes in Patients Undergoing Allogeneic HCT Katie S. Kaminski, PharmD, CPP University of North
More informationEBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda
EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 454 * CHAPTER 30 HSCT for Hodgkin s lymphoma in adults A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 455 CHAPTER 30 HL in adults 1. Introduction
More informationHaploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy
Haploidentical Transplants for Lymphoma Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy HODGKIN NON HODGKIN Non Myelo Ablative Regimen Luznik L et al BBMT 2008 Comparison of Outcomes
More informationRole of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT
Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Stephen Spellman, MBS Director, Immunobiology and Observational Research Assistant Scientific Director CIBMTR,
More informationHOT TOPIC: Matched Related Donor Hematopoietic Stem Cell Transplant for Children with Sickle Cell Disease
November 20, 208 HOT TOPIC: Matched Related Donor Hematopoietic Stem Cell Transplant for Children with Sickle Cell Disease Patricia Kavanagh, MD Associate Professor of Pediatrics Boston University/Boston
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia
More informationLe infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy
Le infezioni fungine nel trapianto di cellule staminali emopoietiche Claudio Viscoli Professor of Infectious Disease University of Genova, Italy Potential conflicts of interest Received grants as speaker/moderator
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_ transplantation_for_primary_amyloidosis 2/2001 11/2018 11/2019 11/2018 Description
More informationCurrent Status of Haploidentical Hematopoietic Stem Cell Transplantation
Current Status of Haploidentical Hematopoietic Stem Cell Transplantation Annalisa Ruggeri, MD, PhD Hematology and BMT Unit Hôpital Saint Antoine, Paris, France #EBMTITC16 www.ebmt.org Hematopoietic SCT
More informationHigh dose cyclophosphamide in HLAhaploidentical
High dose cyclophosphamide in HLAhaploidentical stem cell transplantation Ephraim J. Fuchs, M.D., M.B.A. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins fuchsep@jhmi.edu Alternative Donor Transplantation:
More informationCell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Company Presentation June 2016
Cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders Company Presentation June 2016 Disclaimer These slides and the accompanying oral presentation contain
More informationStem Cell Transplantation
Stem Cell Transplantation Evelyne Willems Centre Hospitalier Universitaire, ULg, Liège Post-ASH meeting, January 11, 2012, Brussels Plan 1. Select the patient: validation of HCT-CI 2. Select the donor
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationHematopoietic Stem Cells, Stem Cell Processing, and Transplantation
Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility Bone Marrow Can Cure: Leukemia Lymphoma Multiple Myeloma Genetic iseases:
More informationBMTCN REVIEW COURSE PRE-TRANSPLANT CARE
BMTCN REVIEW COURSE PRE-TRANSPLANT CARE Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to edit the Master Experts
More informationRapid and Robust CD4+ and CD8+ T-, NK-, BTitel and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood (NiCord) Transplantation
Rapid and Robust CD4+ and CD8+ T-, NK-, BTitel and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood (NiCord) Subtitel Transplantation Boelens/Nierkens lab Jaap Jan Boelens, Central Immune
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationIN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS WITH BRINCIDOFOVIR: FINAL 36 WEEK RESULTS FROM THE ADVISE TRIAL
TREATMENT OF ADENOVIRUS (AdV) INFECTION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS WITH BRINCIDOFOVIR: FINAL 36 WEEK RESULTS FROM THE ADVISE TRIAL Vinod K. Prasad, MD, FRCP 1, Genovefa A. Papanicolaou,
More informationNeuroVia, NV1205 Clinical Trials
NeuroVia, NV1205 Clinical Trials Developing a safe and effective treatment for children with Childhood Cerebral Adrenoleukodystrophy Masoud Mokhtarani MD Chief Medical Officer ALD Life Family Weekend Meeting,
More information